AU2007221470B2 - Phosphatase inhibitor Protein-1 as a regulator of cardiac function - Google Patents

Phosphatase inhibitor Protein-1 as a regulator of cardiac function Download PDF

Info

Publication number
AU2007221470B2
AU2007221470B2 AU2007221470A AU2007221470A AU2007221470B2 AU 2007221470 B2 AU2007221470 B2 AU 2007221470B2 AU 2007221470 A AU2007221470 A AU 2007221470A AU 2007221470 A AU2007221470 A AU 2007221470A AU 2007221470 B2 AU2007221470 B2 AU 2007221470B2
Authority
AU
Australia
Prior art keywords
seq
nucleic acid
protein
amino acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007221470A
Other languages
English (en)
Other versions
AU2007221470A1 (en
Inventor
Evangelia Kranias
Bryan Mitton
Patricia Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2007221470A1 publication Critical patent/AU2007221470A1/en
Application granted granted Critical
Publication of AU2007221470B2 publication Critical patent/AU2007221470B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2007221470A 2006-02-10 2007-02-09 Phosphatase inhibitor Protein-1 as a regulator of cardiac function Ceased AU2007221470B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77232706P 2006-02-10 2006-02-10
US60/772,327 2006-02-10
PCT/US2007/003470 WO2007100465A2 (en) 2006-02-10 2007-02-09 Phosphatase inhibitor protein-1 as a regulator of cardiac function

Publications (2)

Publication Number Publication Date
AU2007221470A1 AU2007221470A1 (en) 2007-09-07
AU2007221470B2 true AU2007221470B2 (en) 2013-02-14

Family

ID=38459499

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007221470A Ceased AU2007221470B2 (en) 2006-02-10 2007-02-09 Phosphatase inhibitor Protein-1 as a regulator of cardiac function

Country Status (7)

Country Link
US (2) US7989606B2 (enExample)
EP (2) EP1994043A4 (enExample)
JP (2) JP2009525757A (enExample)
CN (1) CN101437833A (enExample)
AU (1) AU2007221470B2 (enExample)
CA (1) CA2638913A1 (enExample)
WO (1) WO2007100465A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579519A1 (en) 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
WO2009090049A1 (en) * 2008-01-14 2009-07-23 European Molecular Biology Laboratory Peptides for the specific binding and regulation of protein targets
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CN101942481B (zh) * 2009-04-30 2012-07-25 中南大学 一种针对PKC γ基因RNA干扰的重组慢病毒载体的构建及其应用
KR20130096731A (ko) 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
US10208085B2 (en) 2012-07-05 2019-02-19 Gwangju Institute Of Science And Technology Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
WO2016134300A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
WO2018170310A1 (en) 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
CA3092107A1 (en) 2018-02-28 2019-09-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
AU2020263392A1 (en) 2019-04-26 2021-10-28 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV2.5 vector
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス， インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
CN116490514A (zh) 2020-10-28 2023-07-25 北卡罗来纳-查佩尔山大学 用于双重聚糖结合aav2.5载体的方法和组合物
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
TW202342759A (zh) 2022-02-04 2023-11-01 美商史崔德生物公司 重組腺相關病毒載體及其使用方法
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050894A2 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5753258A (en) 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
US5252348A (en) 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
JPH11514209A (ja) 1995-04-20 1999-12-07 カイロン コーポレイション 組換えレトロウイルス調製物による造血幹細胞の高効率エクスビボ形質導入
AU7665396A (en) 1995-10-27 1997-05-15 Trustees Of The University Of Pennsylvania, The Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
EP0955999B1 (en) 1996-08-19 2001-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Novel liposome complexes for increased systemic delivery
WO1998017683A2 (en) * 1996-10-23 1998-04-30 Duke University Human phosphatase inhibitor-1 gene and methods of screening for non-insulin dependent diabetes mellitus
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
CA2422078C (en) 2000-09-11 2011-08-09 The Regents Of The University Of California High efficiency cardiac gene transfer
US20040214760A1 (en) 2001-01-15 2004-10-28 Ramesh Gupta Inhibition pf protein-phosphatases for the treatment of heart failure
US20020159978A1 (en) 2001-02-06 2002-10-31 James Allen Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
JP2007505628A (ja) 2003-09-19 2007-03-15 チルドレンズ ホスピタル メディカル センター 心収縮能及び心不全傾向の調節
CA2579519A1 (en) * 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050894A2 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bibb, J. A. et al., The Journal of Biological Chemistry 2001, vol. 276, pages 14490-14497 *
Endo, S. et al., Biochemistry 1996, vol. 35, pages 5220-5228 *

Also Published As

Publication number Publication date
US20120053125A1 (en) 2012-03-01
JP2013027398A (ja) 2013-02-07
EP1994043A2 (en) 2008-11-26
EP1994043A4 (en) 2009-05-20
WO2007100465A2 (en) 2007-09-07
JP2009525757A (ja) 2009-07-16
US8524683B2 (en) 2013-09-03
AU2007221470A1 (en) 2007-09-07
CN101437833A (zh) 2009-05-20
CA2638913A1 (en) 2007-09-07
EP2441770A1 (en) 2012-04-18
US20090203596A1 (en) 2009-08-13
WO2007100465A3 (en) 2008-07-31
US7989606B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
US8524683B2 (en) Method for decreasing cardiac using a nucleic acid molecule encoding a variant phosphatase inhibitor-1
WO1999016790A1 (en) Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
US20250073314A1 (en) Lmna gene expression for treatment of laminopathies
WO2001093897A9 (en) Angiostatin and endostatin binding proteins and methods of use
WO2017029206A1 (en) Use of k2p potassium channel for altering the electrophysiology of the heart
WO2016180377A1 (zh) cMLCK基因导入
JP2006515159A (ja) Ｍｋ２相互作用タンパク質
JP4651617B2 (ja) Ｌｋｂ１リン酸化活性を検定する方法
HUT74413A (en) A novel tumor suppressor gene
US20050026233A1 (en) Methods of monitoring and modulating LKB1 activity and its downstream targets
US20060228365A1 (en) Protein and gene involved in myocyte differentiation
EP2328911A1 (en) Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
US20060148057A1 (en) Thioredoxin mutants and uses thereof
HK1129392A (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function
US10835620B2 (en) Methods for treating heart failure using beta-ARKnt peptide
US7303887B2 (en) Mule: Mcl-1 ubiquitination ligase E3
WO2017091807A1 (en) Peptide inhibitors for calcineurin
JP2002509433A (ja) 心筋および骨格筋に特異的な核酸、ならびにその製造方法および使用
JP4147058B2 (ja) 精神分裂病診断剤
이현채 The Role of Adenylyl Cyclase-Associated Protein1 (CAP1) in Transendothelial Migration of Monocytes to Promote Chronic Inflammation
WO2000060083A1 (en) Novel protein associated with cell stress response
CA2268457A1 (en) Mammalian rad1 genes, polypeptides and methods of use
JP2006254766A (ja) インスリン生理活性を調節する活性を有するタンパク質
WO2008098308A1 (en) Agents and methods for treatment of cell proliferative diseases and conditions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired